Be part of the knowledge.™

HDL - Predictor of CV risk and other roles

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Overview
Dr. Philip Barter, director of the Heart Research Institute in Sydney, Australia, shares some of his research on HDL. Not only is it an independent risk factor, even when LDL levels are very low, but it appears to have other roles in the body - including anti-inflammatory, anti-oxidant, and anti-thrombotic.

Philip Barter, MD, PhD

Philip Barter, MD, PhD

Gary Kohn, MD

Recommended

Details

Presenters

Overview
Dr. Philip Barter, director of the Heart Research Institute in Sydney, Australia, shares some of his research on HDL. Not only is it an independent risk factor, even when LDL levels are very low, but it appears to have other roles in the body - including anti-inflammatory, anti-oxidant, and anti-thrombotic.

Philip Barter, MD, PhD

Philip Barter, MD, PhD

Gary Kohn, MD

Program Chapters

Segment Chapters

Playlist:

Recommended

Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future

Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective

CME/CE Broadcast Replay

Identifying the Great Imitator – Demystifying the Systemic Features of IgG4-Related Disease

$IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement$

IgG4-RD Case Conversations: Retroperitoneal Fibrosis with Refractory Ureteral Involvement

Level Up Your Skills: Tailoring Management of HF

Navigating Myasthenia Gravis in Adolescents and Young Adults

Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids

Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF